Our CEO, Cedric Bogaert, shares exciting news:
“Happy to provide insight into a secondary program we’ve applied our focus and technology to. Pancreatic cancer has been and continues to be one of the deadliest tumors (only 12% survival in 5 years), and targets are scarce. Over the past year, myNEO Therapeutics used its discovery pipeline to identify novel targets in pancreatic cancer patients. Building on its successes in colorectal cancer, melanoma, and lung cancer, myNEO has now identified a novel set of targets for these patients, achieving first-in-class coverage and enabling significant advancements over current pancreatic cancer therapies.

This marks the launch of the CAMYO-02 program, which enters further preclinical testing in Q4 2024.